StockData

Mereo BioPharma vs Silence Therapeutics

MREO and SLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MREO and SLN compare

Silence Therapeutics scores higher on the StockData Score (7 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMREOSLN
Size and price
Market cap$219M–
Share price$0.275$19.80
Change, 1 year−84.6%190%
Change, 5 years−85.6%−10.0%
Beta (5Y)2.290.81
Employees3988
StockData Score
Total score17 (better)
Valuation score00
Growth score01 (better)
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/B9.2×–
FCF yield−10.1%–
Growth
Revenue growth (TTM)–−98.2%
Profitability
Gross margin–95.0%
Operating margin–−12344%
Net margin–−11277%
FCF margin–−9682%
Return on equity−76.6%−35.6% (better)
Financial health
Debt / equity–0.00
Interest coverage−440.6×–
Current ratio5.2223.94 (better)
Altman Z-score−4.68–
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions7.1%16.6%
Held by insiders0.18%48.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.